SAGE - Sage Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 58.25B
Enterprise Value 37.04B
Trailing P/E N/A
Forward P/E 1-12.79
PEG Ratio (5 yr expected) 1-0.91
Price/Sales (ttm)5,123.69
Price/Book (mrq)6.84
Enterprise Value/Revenue 34,367.92
Enterprise Value/EBITDA 6-11.03

Trading Information

Stock Price History

Beta (3Y Monthly) 2.26
52-Week Change 310.87%
S&P500 52-Week Change 34.18%
52 Week High 3193.56
52 Week Low 379.88
50-Day Moving Average 3163.45
200-Day Moving Average 3167.99

Share Statistics

Avg Vol (3 month) 3366.8k
Avg Vol (10 day) 3416.95k
Shares Outstanding 551.66M
Float 50.26M
% Held by Insiders 12.71%
% Held by Institutions 198.75%
Shares Short (Aug 15, 2019) 45.54M
Short Ratio (Aug 15, 2019) 414.5
Short % of Float (Aug 15, 2019) 415.77%
Short % of Shares Outstanding (Aug 15, 2019) 410.72%
Shares Short (prior month Jul 15, 2019) 45.23M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-39,682.24%

Management Effectiveness

Return on Assets (ttm)-32.68%
Return on Equity (ttm)-53.75%

Income Statement

Revenue (ttm)1.61M
Revenue Per Share (ttm)0.03
Quarterly Revenue Growth (yoy)-99.00%
Gross Profit (ttm)-191.83M
EBITDA -637.71M
Net Income Avi to Common (ttm)-612.93M
Diluted EPS (ttm)-12.68
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)1.24B
Total Cash Per Share (mrq)23.94
Total Debt (mrq)40.7M
Total Debt/Equity (mrq)3.38
Current Ratio (mrq)16.00
Book Value Per Share (mrq)23.37

Cash Flow Statement

Operating Cash Flow (ttm)-465.24M
Levered Free Cash Flow (ttm)-239.27M